Osaka, Japan

Tae Fukushima

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 14.9

ph-index = 3

Forward Citations = 23(Granted Patents)


Location History:

  • Tokushima, JP (2010 - 2013)
  • Osaka, JP (2013 - 2020)

Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: The Innovative Contributions of Tae Fukushima

Introduction

Tae Fukushima is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing compounds that have therapeutic applications, particularly in treating metabolic and cognitive disorders.

Latest Patents

Fukushima's latest patents include innovative compounds such as cyanotriazole compounds. These compounds are designed to stimulate citric acid cycle activity and improve hyperglycemia with minimal side effects. They are particularly useful in treating conditions like diabetes, insulin resistance, and cardiovascular diseases. Another notable patent involves therapeutic compounds that modulate striatal-enriched tyrosine phosphatase (STEP), which are aimed at treating disorders such as schizophrenia and cognitive deficits.

Career Highlights

Tae Fukushima is currently employed at Otsuka Pharmaceutical Company, Limited, where he continues to advance his research and development efforts. His work has garnered attention for its potential to improve the quality of life for individuals suffering from various health conditions.

Collaborations

Fukushima collaborates with talented colleagues, including Takeshi Kuroda and Takumi Sumida, who contribute to his innovative projects and research initiatives.

Conclusion

Tae Fukushima's contributions to the field of pharmaceuticals through his patents and research are noteworthy. His innovative compounds hold promise for treating significant health issues, showcasing the impact of his work in the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…